Tag - Canaccord Genuity

Profound Medical

Canaccord ups Profound Medical PT to $20 from $14

Canaccord Genuity raised its price target for Profound Medical (NASDAQ:PROF; TSX:PRN) to $20 from $14 after the company announced preliminary Q4-2019 results. Shares of Profound were quoted at $14.72, up $1.73, or 13%...

Canaccord cuts Vermillion to hold; PT to $1

Canaccord Genuity downgraded Vermillion (NASDAQ:VRML) to “hold” from “buy” and lowered its price target to $1 from $2.25 after the company’s first quarter results missed estimates across the board. The stock closed at...